7/14/2023 0 Comments Apg conference 2021![]() This study showed, compared to the wild-type cell line, the NSCLC cell line harboring STK11/LKB1 mutations was highly sensitive to APG-115. In addition, STK11/LKB1 mutations also have implications on cysteine metabolism. ![]() STK11/LKB1 mutations are a main driver of drug resistance to PD-1 inhibitors in patients with KRAS-mutant lung adenocarcinoma, therefore could predict the poor prognosis of immunotherapy in these patients. STK11/LKB1 mutations affect the tumor immune microenvironment, and are associated with the reduction of invasive cytotoxic CD8+T-cells in both patient-derived xenograft (PDX) models and mouse models. STK11/LKB1 and KRAS co-mutations represent one of the three common oncogenic subtypes of KRAS-mutant lung adenocarcinoma. Results from this study showed that APG-115 has therapeutic potential in NSCLC harboring STK11 mutations, and shows the potential of a new treatment option for the subgroup of patients with drug resistance to approved PD-1 inhibitors. Sun was titled “MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models of NSCLC Harboring STK11 Mutations”. APG-115 is the first MDM2-p53 inhibitor entering clinical development in China, and is currently being investigated in multiple Phase Ib/II clinical studies in solid tumors and hematologic malignancies in China and the US. APG-115 has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction. The World Conference on Lung Cancer, organized by the International Association for the Study of Lung Cancer (IASLC), is the world’s largest multidisciplinary scientific conference that focuses on the cutting-edge research and clinical advancements in the field of lung cancer and other thoracic malignancies.ĪPG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. Yilong Wu’s research team at Guangdong Lung Cancer Research Institute. Hao Sun, from Guangdong Provincial People’s Hospital and Dr. 2, 2021 - Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company recently released the results from a preclinical study of APG-115, a novel MDM2-p53 inhibitor being developed by Ascentage Pharma, in the treatment of non-small cell lung cancer (NSCLC) harboring STK11 mutations through an oral presentation on January 29, 2021, at the 2020 World Conference on Lung Cancer (WCLC 2020).
0 Comments
Leave a Reply. |